Latest Breaking News On - Kaken pharmaceutical co - Page 5 : vimarsana.com

Argentum Pharmaceuticals and Bausch Health Settle Patent Dispute Over JUBLIA® News provided by Share this article Share this article NEW YORK, Jan. 13, 2021 /PRNewswire/  Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Bausch Health US, LLC and Kaken Pharmaceutical Co., LTD., related to Argentum s inter partes review petition challenging an Orange Book-listed patent for JUBLIA® (efinaconazole) Topical Solution. Argentum filed its IPR petition against U.S. Patent 7,214,506 (the 506 Patent ) on May 12, 2017. Argentum and Kaken entered into a confidential settlement agreement and filed a joint motion to terminate Argentum s IPR on November 12, 2020, prior to a decision on Argentum s petition by the Patent Trial & Appeal Board. On January 8

Zydus pharmaceuticals united states incArgentum pharmaceuticalsValeant pharmaceuticals north americaKaken pharmaceutical coBausch healthOrange book listedPatent trialAppeal boardUnited statesஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க்பாஷ் ஆரோக்கியம்ஆரஞ்சு நூல் பட்டியலிடப்பட்டுள்ளதுகாப்புரிமை சோதனைமுறையீடு பலகைஒன்றுபட்டது மாநிலங்களில்